Catalog No.
DHE03401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
CD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P33681
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IDEC-114, CAS: 357613-77-5
Clone ID
Galiximab
Galiximab: a review, PMID: 20092425
The use of galiximab in non-Hodgkin lymphoma, PMID: 18854281
Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs, PMID: 22267549
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine, PMID: 23764770
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma, PMID: 15994148
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness, PMID: 29390097
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance), PMID: 23194022
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma, PMID: 17470451
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness, PMID: 22357442
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis, PMID: 15093549
Galiximab in relapsed hodgkin lymphoma, PMID: 21317862
Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma, PMID: 12672278
Newer monoclonal antibodies for hematological malignancies, PMID: 18565392
Emerging drugs for chronic lymphocytic leukaemia, PMID: 16503834
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma, PMID: 17335294
Gateways to clinical trials, PMID: 16357953
Gateways to clinical trials, PMID: 15319815
Gateways to clinical trials, PMID: 12851663
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma, PMID: 20425465
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials, PMID: 30575311
Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary, PMID: 21793791
Recombinantly engineered human proteins: transforming the treatment of psoriasis, PMID: 12482385
The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia, PMID: 23667725
CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease, PMID: 33506028
Gateways to clinical trials. March 2003, PMID: 12731460
CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma, PMID: 22076940
IDEC-114 (IDEC), PMID: 11569938
Combination treatment approaches and novel therapies for lymphoma, PMID: 18154235
Association of rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboons, PMID: 15069178
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody, PMID: 12399760
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma, PMID: 18998258
For research use only. Not for human or drug use.
